Fragmentation and tag fragmentation methods for next generation sequencing analysis and like

Abstract

Provided is a method for efficiently generating a double-stranded DNA library having different tag fragment sequences on the 5'end side and the 3 'end side by a simple step. The method comprises the following steps (i) to (iii): (i) fragmenting double-stranded DNA by using a transposon; and a step for linking, as a transfer strand, either a first adapter comprising a first tag fragment sequence and a first transposon terminal sequence or a second adapter comprising a second transposon terminal sequence and a second tag fragment sequence, to the 5'terminal or 3 'terminal of the double-stranded DNA, said transposon comprising (a) a first adapter comprising a first tag fragment sequence and a first transposon terminal sequence, and (b) a second adapter comprising a second transposon terminal sequence and a second transposon terminal sequence. (c) a transposase comprising a second transposon terminal sequence having a base sequence complementary to at least a portion of the first transposon terminal sequence, and (c) a transposase; (ii) a step in which an additional oligomer containing a second tag fragment sequence is linked to the second linker; and (iii) a step for linking a non-transfer chain linker, which is not linked to the double-stranded DNA, among the first linker and the second linker, to a terminal of a linker, which is not linked to a transfer chain in step (i), among the 5'terminal and the 3 'terminal of the double-stranded DNA.

Description

Technical Field

[0001] The present invention relates to a method for generating a double-stranded DNA library, etc. Background Art

[0002] In recent years, the analysis using the next generation sequencer (NGS) has been widely used, and various pre-treatment technologies such as double-stranded DNA fragmentation and label fragment addition for the analysis have been developed. For example, the following method is known: a first label fragment sequence or a second label fragment sequence is respectively given to a recombinase such as a transposase to form two transposons, and the target double-stranded DNA is randomly fragmented and labeled using these two transposons. However, in this method, the two transposons are randomly combined with the ends of the target double-stranded DNA, so in addition to the theoretical yield being reduced to one-half, there are also problems such as not being able to retain chain information and not being able to be used for bisulfite sequence analysis.

[0003] In recent years, RNA sequence analysis, which chain in the double-stranded genomic DNA is used to transcribe RNA, that is, the RNA sequence analysis method that retains the chain information has received attention in recent years. By using chain information, it is not only possible to analyze non-coding genes such as antisense RNA, but also to more accurately quantify the expression of overlapping genes. Therefore, the development of fragmentation and label fragment addition methods for retaining chain information has also been carried out. For example, a method for adding a Y-shaped linker after fragmentation (patent document 1) and a method for only labeling the 5' end side with the first label fragment sequence after transposase fragmentation, then removing the linker on the 3' end side by heat treatment, etc. and replacing the second label fragment sequence (patent document 2 and non-patent document 1) have been reported.

[0004] Prior art literature

[0005] Patent Literature

[0006] Patent Document 1: U.S. Patent No. 8563478

[0007] Patent Document 2: U.S. Patent No. 10287574

[0008] Non-patent literature

[0009] Non-patent literature 1: Wang et al., Nature Protocols Vol.8, No.10, 2022-2032, 2013 Summary of the invention

[0010] Problem that the invention aims to solve

[0011] The previous methods of fragmenting double-stranded DNA and adding label fragments while retaining chain information usually have complicated steps, low collection efficiency, or both. For example, in Patent Document 1, fragmentation reaction and adenine addition reaction are usually required before adding the Y-shaped linker, and the linker dimer needs to be removed after adding the Y-shaped linker, which is not only complicated and laborious, but also has low collection efficiency. In addition, in the case of Patent Document 2 and Non-Patent Document 1, as known from the embodiments, after using transposase fragmentation and only fragmenting the 5' terminal side tag, it is necessary to remove the linker on the 3' terminal side and give a new linker containing other tag fragment sequences. In order to complete this step, it is necessary to change the temperature in multiple steps. Carrying out such a multi-step process not only has complicated steps, but also produces losses at each stage of the steps, and there is a problem of reduced yield of the double-stranded DNA library finally generated. One of the subjects of the present invention is to provide a method for efficiently fragmenting and labeling double-stranded DNA through simple steps.

[0012] Solutions for solving problems

[0013] The present inventors have conducted in-depth research to solve the above-mentioned problems, and as a result, have discovered a method that can efficiently fragment double-stranded DNA and add tag fragments with different sequences at the 5' end and 3' end using simpler steps than previous methods. Specifically, after the double-stranded DNA is fragmented using a transposase that has been endowed with a first tag fragment sequence, a second tag fragment sequence is connected to the linker using a ligase or the like without removing the linker at the 3' end, thereby enabling simple and efficient fragmentation and the addition of the first tag fragment sequence and the second tag fragment sequence. Based on this insight, further in-depth research was repeated, resulting in the completion of the present invention.

[0014] That is, the present invention typically includes the following aspects.

[0015] [Item 1] A method for generating a double-stranded DNA library having different tag fragment sequences at the 5' end and the 3' end, comprising the following steps (i) to (iii):

[0016] (i) fragmenting the double-stranded DNA using a transposome, and connecting any one of the following first linker and the following second linker to the 5' end or the 3' end of the double-stranded DNA as a transfer strand, wherein the transposome comprises:

[0017] (a) a first adapter, which comprises a first tag fragment sequence and a first transposon end sequence,

[0018] (b) a second adaptor comprising a second transposon end sequence having a base sequence complementary to at least a portion of the first transposon end sequence, and

[0019] (c) transposase;

[0020] (ii) a step of connecting an additional oligomer containing a second tag fragment sequence to the second linker; and

[0021] (iii) a step of ligating the non-transferred strand linker of the first linker and the second linker that is not linked to the double-stranded DNA to the end of the 5' end and the 3' end of the double-stranded DNA that is not linked to the transferred strand linker in the step (i),

[0022] The step (ii) is performed before or after the step (iii), or simultaneously with the step (iii).

[0023] [Item 2] The method according to Item 1, wherein the first adapter contains a first tag fragment sequence at the 5' end side of the first transposon end sequence, and the first adapter becomes a transferred strand connected to the 5' end of the double-stranded DNA by a transposase.

[0024] [Item 3] The method according to Item 1 or 2, wherein the additional oligomer comprises a base sequence complementary to a portion of the base sequence of the first linker.

[0025] [Item 4] The method according to any one of Items 1 to 3, wherein the transposase is a highly active Tn5 transposase, and the first transposon end sequence and the second transposon end sequence are Tn5-type transposon end sequences.

[0026] [Item 5] The method according to any one of Items 1 to 4, wherein in the step (ii), the additional oligomer is ligated to the second linker using DNA ligase.

[0027] [Item 6] The method according to any one of Items 1 to 5, wherein in the step (iii), a linker that is not ligated to the non-transferred strand of the double-stranded DNA is ligated to the double-stranded DNA using a DNA polymerase and a DNA ligase.

[0028] [Item 7] The method according to any one of Items 1 to 6, wherein in the step (iii), the linker not connected to the non-transferred strand of the double-stranded DNA is a second linker whose 5' terminal side is phosphorylated, and the second linker is connected to the 3' terminal of the double-stranded DNA.

[0029] [Item 8] A method according to any one of Items 1 to 7, wherein in the step (i), a first linker is connected to the 5' end of the double-stranded DNA as a transfer strand, and in the step (ii), an additional oligomer whose 5' end side is phosphorylated is connected to the 3' end of the second linker.

[0030] [Item 9] A method according to any one of Items 1 to 8, wherein in the step (i), a first linker is connected to the 5' end of the double-stranded DNA as a transfer strand, and in the step (ii), an additional oligomer having a modified OH group on the 3' end side is connected to the 3' end of the second linker.

[0031] [Item 10] The method according to Item 9, wherein the modification of the OH group is modification using a phosphate group or reverse dT.

[0032] [Item 11] The method according to any one of Items 1 to 10, wherein a double-stranded DNA library retaining strand information is generated.

[0033] [Item 12] The method according to any one of Items 1 to 11, wherein at least one strand of the double-stranded DNA is modified.

[0034] [Item 13] The method according to Item 12, wherein the modification is a methylation modification.

[0035] [Item 14] A method according to Item 12, wherein a double-stranded DNA library for bisulfite analysis is generated using the first linker in which the cytosine base in the first tag fragment sequence has been methylated and the additional oligomer in which the cytosine base in the second tag fragment sequence has been methylated.

[0036] Effects of the Invention

[0037] According to the present invention, double-stranded DNA can be efficiently fragmented and tag fragments with different sequences can be added to the 5' end and the 3' end using simpler steps than the previous methods. The method of the present invention does not require the preparation of two different transposons. According to the method of the present invention, the strand information can also be easily retained. Thus, sequence analysis represented by NGS can be efficiently and advancedly performed from trace samples, which greatly contributes to the advancement of gene analysis and diagnostic technology. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1This is a schematic diagram of one embodiment of the present invention. After adding a first linker having a first tag fragment sequence and a first transposon end sequence and a second linker having a second transposon end sequence to double-stranded DNA using a tagmentase such as a transposase, an additional oligomer having a second tag fragment sequence is connected to the second linker, and a linker (non-transferred strand, the second linker in this figure) that is not connected (covalently bound) to the double-stranded DNA is connected to the double-stranded DNA, thereby generating a double-stranded DNA library having different tag fragment sequences at the 5' end and the 3' end.

[0039] Figure 2 This is one embodiment of the present invention, and is a schematic diagram of the case where a first linker consisting of a base sequence shown in sequence number 3, a second linker consisting of a base sequence shown in sequence number 4, and an additional oligomer consisting of a base sequence shown in sequence number 5 are used. The 5' ends of the second linker and the additional oligomer are phosphorylated to enable ligation to adjacent DNA. In addition, the 3' end of the additional oligomer is reverse-dT-modified to prevent the oligomer from decomposing and from acting as a primer in a PCR reaction or the like.

[0040] Figure 3 is one embodiment of the present invention, and is a schematic diagram of the case where a first linker consisting of a base sequence as shown in SEQ ID NO: 6, a second linker consisting of a base sequence as shown in SEQ ID NO: 7, and an additional oligomer consisting of a base sequence as shown in SEQ ID NO: 8 (the base sequence lengths of the first linker and the second linker are respectively 1:1 and 2:1, respectively). Figure 2 The example of the short example). The 5' end of the second linker and the additional oligomer is phosphorylated to enable ligation to the adjacent DNA. In addition, the 3' end of the additional oligomer is reverse dT-modified to prevent the oligomer from decomposing and prevent it from acting as a primer in PCR reactions, etc.

[0041] Figure 4 It is an embodiment of the present invention, and is a schematic diagram of the use of a first linker composed of a base sequence shown in sequence number 9, a second linker composed of a base sequence shown in sequence number 10, and an additional oligomer composed of a base sequence shown in sequence number 11 (an example in which the first tag fragment sequence in the first linker and the second tag fragment sequence in the additional oligomer are not arranged at the ends, but the first tag fragment sequence and the second tag fragment sequence form a ring structure). By phosphorylating the 5' ends of the second linker and the additional oligomer, it is possible to connect to the adjacent DNA. In addition, by reverse dT modification of the 3' end of the additional oligomer, it is prevented from acting as a primer in PCR reactions, etc. while preventing decomposition.

[0042] Figure 5 This is a diagram showing the electrophoresis results of the library product (linker 2) in Example 1. The library product pattern was confirmed using the microchip electrophoresis apparatus MultiNA for DNA / RNA analysis produced by SHIMADZU.

[0043] Figure 6 This is a diagram showing the electrophoresis results of the library product (linker 3) in Example 2. The pattern of the library product was confirmed using the microchip electrophoresis apparatus MultiNA for DNA / RNA analysis produced by SHIMADZU. DETAILED DESCRIPTION

[0044] [Disclosure of the Invention]

[0045] The present invention will be described in more detail below by showing embodiments of the present invention.

[0046] <Method for generating double-stranded DNA library>

[0047] The present invention provides a method for generating a double-stranded DNA library having different tag fragment sequences at the 5' end and the 3' end using simpler steps than the previous methods. In the present invention, after the double-stranded DNA is fragmented using a transposome comprising a first linker containing a first tag fragment sequence, a second linker and a transposase, an additional oligomer containing a second tag fragment sequence is connected to the second linker using a ligase or the like, thereby enabling simple and efficient fragmentation of the double-stranded DNA and the addition of the first tag fragment sequence and the second tag fragment sequence. The method of the present invention can be used to perform fragmentation and addition of tag fragment sequences required for sequence analysis represented by NGS. Furthermore, in the tag fragmentation of the present invention, different tag fragment sequences are added at the 5' end and the 3' end, so that, for example, a double-stranded DNA library can be prepared in a state where the chain information is retained.

[0048] 1. Addition of the first tag fragment sequence and the second tag fragment sequence

[0049] In the present invention, a double-stranded DNA library having different tag fragment sequences at the 5' end and the 3' end is generated by a method comprising at least the following steps (i) to (iii):

[0050] (i) fragmenting the double-stranded DNA using a transposome, and connecting any one of the following first linker and second linker to the 5' end or 3' end of the double-stranded DNA as a transferred strand, wherein the transposome comprises:

[0051] (a) a first adapter, which comprises a first tag fragment sequence and a first transposon end sequence,

[0052] (b) a second adaptor comprising a second transposon end sequence having a base sequence complementary to at least a portion of the first transposon end sequence, and

[0053] (c) transposase;

[0054] (ii) a step of connecting an additional oligomer containing a second tag fragment sequence to the second linker; and

[0055] (iii) a step of ligating the non-transferred strand linker of the first linker and the second linker that is not linked to the double-stranded DNA to the end of the 5' end or 3' end of the double-stranded DNA that is not linked to the transferred strand linker in the step (i).

[0056] It should be noted that the order of step (ii) and step (iii) among these steps is not limited, and step (ii) may be performed before step (iii), step (iii) may be performed before step (ii), or step (ii) and step (iii) may be performed simultaneously.

[0057] In the present invention, in the above step (i), the double-stranded DNA is fragmented using the transposome comprising the above (a), (b) and (c), and the first linker or the second linker is connected to the 5' end or the 3' end of the double-stranded DNA as a transfer strand. In this step, the end to which the transfer strand is connected may be either the 5' end or the 3' end. In one embodiment, the first linker or the second linker is preferably connected to the 5' end as a transfer strand, and the first linker is preferably connected to the 5' end as a transfer strand.

[0058] 2. (a) First linker and (b) Second linker

[0059] In the present invention, a transposome comprising (a) a first linker and (b) a second linker together with (c) a transposase is used. The (a) first linker constituting the transposome of the present invention is a polynucleotide comprising at least a first tag fragment sequence and a first transposon end sequence. In the first linker, in addition to the first tag fragment sequence and the first transposon end sequence, one or more base sequences of arbitrary length (for example, a length of about 5 to 30 bp, preferably a length of about 7 to 25 bp, and more preferably a length of about 15 to 20 bp) may be included (in this specification, also referred to as "an arbitrary sequence of the first linker", etc.). The arbitrary sequence of the first linker may be present between the first tag fragment sequence and the first transposon end sequence, and / or may be present on the side adjacent to the first tag fragment sequence and opposite to the first transposon end sequence (for example, the 5' end side of the first tag fragment sequence when the first linker is connected to the 5' end as a transfer chain). In a specific embodiment, the arbitrary sequence of the first linker is designed in a manner to complementarily bind to a portion of the additional oligomer described later (except the second tag fragment sequence) (preferably, the arbitrary sequence of the first linker is designed in a manner to complementarily bind to a portion of the additional oligomer described later (except the second tag fragment sequence) together with a portion of the first transposon end sequence), thereby facilitating the connection between the additional oligomer and the second linker. In this case, the arbitrary sequence of the first linker is also referred to as a "sequence complementary to the additional oligomer". It should be noted that the regions of the first tag fragment sequence region and the first transposon end sequence region (and the region of the arbitrary sequence of the first linker included as needed) do not need to be clearly distinguished, and their partial sequences may overlap.

[0060] The (b) second linker constituting the transposome of the present invention is a polynucleotide that contains at least a second transposon end sequence, preferably consisting of a second transposon end sequence. The above-mentioned second transposon end sequence preferably has a base sequence that is complementary to at least a portion of the above-mentioned first transposon end sequence. Thus, the first transposon end sequence contained in the first linker and the second transposon end sequence contained in the second linker contain base sequences that are complementary to each other, thereby, the first linker and the second linker can form a double strand in at least a portion of the region (preferably the region on the end side that is ultimately transferred to the fragmented double-stranded DNA) with the help of complementary base sequences, and are easily added to the end of the fragmented double-stranded DNA.

[0061] There is no particular restriction on the first tag fragment sequence contained in the first linker and the second tag fragment sequence to be connected to the second linker, and the first tag fragment sequence and the second tag fragment sequence are preferably not complementary. For example, the consistency between the base sequence of the reverse complementary chain of the first tag fragment sequence and the base sequence of the second tag fragment sequence is preferably 70% or less, more preferably 60% or less, and further preferably 50% or less. In addition, the lower limit of the consistency between the base sequence of the reverse complementary chain of the first tag fragment sequence and the base sequence of the second tag fragment sequence is not particularly limited, preferably more than 0%, preferably more than 1%. Sequence consistency can be determined using programs such as Blast and Clustal W. Thus, by designing in a manner that the base sequence consistency between the base sequence of the reverse complementary chain of the first tag fragment sequence and the base sequence of the second tag fragment sequence is low, the first tag fragment sequence and the second tag fragment sequence respectively assigned to the two ends of the double-stranded DNA can be more clearly identified, and it is easier to distinguish the 5' end side and the 3' end side of the double-stranded DNA to which the first tag fragment sequence or the second tag fragment sequence is added.

[0062] In a preferred embodiment, (a) the first linker (particularly the region other than the first tag fragment sequence, preferably the region of any sequence of the first linker and / or a part of the first transposon end sequence) preferably has a base sequence consisting of several bases (for example, 7 bp or more, preferably 10 bp or more, more preferably 12 bp or more, and further preferably 15 bp or more, with no particular upper limit, for example, 30 bp or less) complementary to the base sequence of the additional oligomer (particularly other than the second tag fragment sequence). Thus, by including a base sequence in which the base sequence of the first linker and the base sequence of the additional oligomer are complementary to each other, the additional oligomer in step (ii) is not easily connected to the end of the first linker, but is easily complementary to the first linker. Thus, the additional oligomer is arranged close to the second linker that is complementary to the first linker, and as a result, the additional oligomer is easily connected to the end of the second linker.

[0063] In a more specific embodiment, the 5' end of the linker that is not the transferred chain in step (i) in the first linker and the second linker is preferably modified by phosphorylation, etc. Thus, by modifying the 5' end of the linker that is not the transferred chain in step (i) (also referred to as the linker of the non-transferred chain) by phosphorylation, etc. in advance, the linker of the non-transferred chain can be easily ligated to the double-stranded DNA in step (iii) using, for example, DNA ligase.

[0064] In a more preferred embodiment, the first linker is preferably a transferred strand containing the first tag fragment sequence at the 5' end side of the first transposon end sequence and connected to the 5' end of the double-stranded DNA using a transposase. In this embodiment, the second linker is preferably a non-transferred strand whose 5' end is modified by phosphorylation or the like and can be connected to the 3' end of the double-stranded DNA using a DNA ligase or the like.

[0065] 3. Attaching oligomers

[0066] In the present invention, the oligoDNA (referred to as an additional oligomer) used to connect to the second linker contains a second tag fragment sequence. The additional oligomer preferably has a base sequence formed by a series of several bases (e.g., more than 7bp, preferably more than 10bp, more preferably more than 12bp, and further preferably more than 15bp, with no particular upper limit, for example, less than 30bp) complementary to the base sequence of the first linker (especially the region outside the first tag fragment sequence, preferably the region of the arbitrary sequence of the first linker and / or a part of the first transposon end sequence). It should be noted that the region of the second tag fragment sequence and the region of the base sequence complementary to the base sequence of the first linker (especially the region outside the first tag fragment sequence, preferably the region of the arbitrary sequence of the first linker and / or a part of the first transposon end sequence) do not need to be clearly distinguished, and their partial sequences may overlap. By making the additional oligomer contain a base sequence complementary to the base sequence of the first linker (particularly a region other than the first tag fragment sequence, preferably a region of an arbitrary sequence of the first linker and / or a portion of the first transposon end sequence), the additional oligomer in step (ii) is not easily connected to the end of the first linker, but is easily complementary to the first linker. As a result, the additional oligomer is arranged close to the second linker that is complementarily bound to the first linker, and is easily connected to the end of the second linker.

[0067] In one embodiment, the additional oligomer may include a nucleic acid analog such as a locked nucleic acid (LNA) or a bridged nucleic acid (BNA). By making the bases constituting the additional oligomer include such nucleic acid analogs such as LNA and BNA, the annealing temperature of the first linker and the additional oligomer can be increased, thereby having the advantage that the additional oligomer is more likely to complementarily bind to the base sequence of the first linker.

[0068] The additional oligomer used in the present invention may contain, in addition to the second tag fragment sequence and the base sequence complementary to the base sequence of the first linker, one or more base sequences of arbitrary length (for example, a length of about 5 to 30 bp, preferably a length of about 10 to 25 bp, and more preferably a length of about 15 to 20 bp) (also referred to as "an arbitrary sequence of the additional oligomer" in this specification, etc.). The arbitrary sequence of the additional oligomer may be present on either the 5' end side or the 3' end side of the second tag fragment sequence. From the viewpoint of not easily interfering with the connection between the additional oligomer and the second linker, it is preferably present on the side adjacent to the second tag fragment sequence and opposite to the end to which the second linker is connected (for example, the 3' end side of the second tag fragment sequence when the first linker is connected to the 5' end as a transfer chain).

[0069] 4.(c) Transposase and transposon end sequences

[0070] The transposase used in the present invention is not particularly limited, and any transposase or mutant thereof known in the art can be used. Examples include Tn3 transposase, Tn5 transposase, Tn7 transposase, Tn10 transposase, MuA transposase, Sleeping Beauty transposase, piggyBac transposase, Himar1 transposase, Mos1 transposase, or mutants thereof (e.g., mutants having an amino acid sequence obtained by replacing, deleting, inserting or adding 1 or several (e.g., 1 to 10, preferably 1 to 5, more preferably about 1 to 3) amino acids in the wild-type amino acid sequence), but are not limited thereto.Among them, Tn5 transposase, MuA transposase, Sleeping Beauty transposase, piggyBac transposase, Himar1 transposase, Mos1 transposase, or mutants thereof, which are known as hyperactive mutants, are preferred (e.g., Picelli et al., Genome Res. 24(12): 2033-40, 2014, M. Zhou and W. S. Reznikoff, J. Mol. Biol., 271, 362-373, 1997, T. W. Weigand and W. S. Reznikoff, J. Bacteriol., 174, 1229-1239, 1992, MD Weinreich, A. Gasch and W. S. Reznikoff, Genes Dev., 8, 2363-2374, 1994, T. A. Naumann and W. S. Reznikoff, Proc. Natl. Acad. Sci. USA 97, 8944-8949, 2000, I. Y. Goryshin and W. S. Reznikoff, J. Biol. Chem. 273, 7367-7374, 1998, the Tn5 transposase mutant described in F. Voigt et al., Nat. Commun., Vol. 7, No. 11126, 2016, the Sleeping Beauty transposase mutant described in K. Yusa et al., Proc. Natl. Acad. Sci. USA, Vol. 108 No. 4 1531-1536, 2010, DJ Lampe et al. al., Proc. Natl. Acad. Sci. USA, Vol. 96, No. 20, 11428-11433, 1999, the Himar1 transposase mutant described in S. Germon et al., Genetica, Vol. 137, No. 265, 265-276, 2009, the MuA transposase mutant described in TSRasila et al., Nucleic Acids Res. Vol. 46, Issue 9, 4649-4661, 2018, etc.), more preferably Tn5 transposase or a Tn5-type transposase as a mutant thereof, and particularly preferably a Tn5 transposase mutant (highly active Tn5 transposase).

[0071] The transposon end sequence used in combination with the transposase (referring to a specific double-stranded sequence recognized by the transposase. Usually, one strand is the transferred strand and the other strand is the non-transferred strand.) varies depending on the transposase used. Those skilled in the art can appropriately select a suitable transposon end sequence based on technical common sense and the type of transposase used.

[0072] In addition, the transposon end sequence used in the present invention may not be a full-length sequence, and may be a portion of a base sequence known as a transposon end sequence as long as the effect of the present invention can be exerted. For example, a transposon end sequence confirmed to be a non-transferred strand may be used in the present invention as long as it is at least 10 bp (preferably at least 11 bp, more preferably at least 12 bp) in length. For example, in the present invention, a portion of a transposon end sequence in which a base sequence of a transposon end sequence known to be a non-transferred strand is deleted by at least 10 bp (preferably at least 11 bp, more preferably at least 12 bp) of base length on the 3' end side can be preferably used.

[0073] For example, when using a Tn5-type transposase, you can use:

[0074] 5'-AGATGTGTATAAGAGACAG-3' (SEQ ID NO: 1)

[0075] As the transposon end sequence to be the transferred strand, the following sequences can be used as the complementary strand:

[0076] 5'-CTGTCTCTTATACACATCT-3' (SEQ ID NO: 2)

[0077] The sequences are used as transposon end sequences that become non-transferred chains.

[0078] Note that, as shown in Patent Document 2, the transposon end sequence used when the transposase exhibits transfer activity on double-stranded DNA is not the one shown here, and any transposon end sequence that the transposase used exhibits transfer activity can be used in the present invention.

[0079] In one embodiment, in the first adapter, the first tag fragment sequence and the sequence complementary to the additional oligomer are added to the 5' end of the first transposon end sequence. Figure 2 Use as shown:

[0080] 5'-TCGTCGGCAGCGTCCTCGTGTGCTACTTGAAGATGTGTATAAGAGACA G-3' (SEQ ID NO: 3)

[0081] As the first linker to transfer strands, use:

[0082] 5'-CTGTCTCTTATACACATCT-3' (SEQ ID NO: 4)

[0083] As a second linker for the non-transferred strand, and using:

[0084] 5'-TCAAGTAGCACACGAGCCGAGCCCACGAGAC-3' (SEQ ID NO: 5) is used as the additional oligomer. It should be noted that the 5' end of the second linker and the additional oligomer may be phosphorylated. In addition, the OH group at the 3' end of the additional oligomer may be modified (for example, with a phosphate group or reverse dT).

[0085] In another embodiment, the non-transferred strand can be truncated. For example, the full length of the non-transferred strand (or the second adaptor that can become the non-transferred strand) can be shortened to about 10 bp to 19 bp, and preferably about 11 bp to 19 bp, more preferably about 12 bp to 19 bp, and even more preferably about 14 bp to 19 bp can be used.

[0086] For example, you can Figure 3 Use as shown:

[0087] 5'-TCGTCGGCAGCGTCAGCTAGCTAGCAGATGTGTATAAGAGACA G-3' (SEQ ID NO: 6)

[0088] As the first linker to transfer strands, use:

[0089] 5'-CTGTCTCTTATACAC-3' (SEQ ID NO: 7)

[0090] As a second linker for the non-transferred strand, and using:

[0091] 5'-ATCTGCTAGCTAGCTCCGAGCCCACGAGAC-3' (SEQ ID NO: 8)

[0092] As an additional oligomer. It should be noted that the 5' end of the second linker and the additional oligomer may be phosphorylated. In addition, the OH group at the 3' end of the additional oligomer may be modified (for example, with a phosphate group or reverse dT).

[0093] When the adapter of the non-transferred strand is shortened in this manner, a stable tag fragment sequence can be formed together with an additional oligomer and added to the double-stranded DNA together with the adapter of the transferred strand.

[0094] In another embodiment, the first tag fragment sequence may be incorporated into the sequence complementary to the additional oligomer in the first linker. In other words, the sequence complementary to the additional oligomer may be present at the 5' end and the 3' end of the first tag fragment sequence.

[0095] For example, you can Figure 4 Use as shown:

[0096] 5'-CTCGTGTGCTACTTGATCGTCGGCAGCGTCAGATGTGTATAAGA GACAG-3' (SEQ ID NO: 9)

[0097] As the first linker to transfer strands, use:

[0098] 5'-CTGTCTCTTATA-3' (SEQ ID NO: 10)

[0099] As a second adapter for the non-transferred strand, and used

[0100] 5'-CACATCTCCGAGCCCACGAGACTCAAGTAGCACACGAG-3' (SEQ ID NO: 11)

[0101] As an additional oligomer. It should be noted that the 5' end of the second linker and the additional oligomer may be phosphorylated. In addition, the OH group at the 3' end of the additional oligomer may be modified (for example, with a phosphate group or reverse dT).

[0102] When such a first linker, a second linker, and an additional oligomer are used, a ring structure is formed in which the first tag fragment sequence and the second tag fragment sequence are sandwiched by the double-stranded region, and the present invention can be a method of adding such a tag fragment sequence to double-stranded DNA. By forming such a ring structure, the first tag fragment sequence and the second tag fragment sequence are present at a position closer to the end of the double-stranded DNA, which has the following advantages, for example: when PCR is performed using primers corresponding to the first tag fragment sequence and the second tag fragment sequence, the reaction can be performed more efficiently.

[0103] 5. Preparation of Transposomes

[0104] The transpososome used in the present invention is characterized in that it contains at least the above-mentioned (a) first linker, (b) second linker and (c) transposase. There is no particular limitation on the method of imparting the first linker and the second linker to the transposase, and for example, in addition to non-patent document 1, the method described in Picelli et al., Genome Res. 24 (12): 2033-40, 2014, etc. can be cited.

[0105] 6. Reaction temperature and time of transposase treatment (step of reacting (i) transposome with double-stranded DNA)

[0106] The temperature for reacting the transposome with the double-stranded DNA can be appropriately set according to the transposase used, the sequence and length of the first linker, the sequence and length of the second linker, and a combination of these. For example, as a reaction temperature, it is preferably above 30°C and below 65°C, more preferably above 37°C and below 60°C, and further preferably above 50°C and below 60°C. As a reaction time, it is preferably more than 1 minute, more preferably, more preferably more than 3 minutes, and further preferably more than 5 minutes. The upper limit of the reaction time is not particularly limited, and can be, for example, less than 24 hours, preferably less than 12 hours, more preferably less than 6 hours, and further preferably less than 3 hours.

[0107] The concentration of transposase in the reaction solution for reacting the transposome with double-stranded DNA is not particularly limited as long as it shows transposase activity, and is preferably above 10 pg / μL. In addition, as the reaction solution used in the transposase treatment, as long as it is a reaction solution that exerts transposase activity, it is not particularly limited and may contain other additives. For example, it is known that the addition of N,N-dimethylformamide and polyethylene glycol can improve the efficiency of NGS library preparation using transposon reactions, and can be preferably used (Picelli et al., Genome Res. 24 (12): 2033-40, 2014). In addition, for example, buffers, salts, organic solvents, polymers, surfactants, chelating agents, proteins, combinations of two or more of these, etc. can be used as additives.

[0108] Examples of the buffer include Tris, Bis-Tris, Tricine, Bis-Tricine, Hepes, Mops, Tes, Taps, Pipes, Caps, phosphoric acid, acetic acid, and combinations of two or more thereof. The buffer is usually dissolved in water (preferably nuclease-free water) and used in the form of an aqueous solution.

[0109] Examples of the salt include chlorides (e.g., lithium chloride, sodium chloride, potassium chloride, magnesium chloride, manganese chloride, and ammonium chloride), acetates (e.g., lithium acetate, sodium acetate, potassium acetate, magnesium acetate, manganese acetate, and ammonium acetate), sulfates (e.g., potassium sulfate, magnesium sulfate, manganese sulfate, and ammonium sulfate), and combinations of two or more thereof.

[0110] Examples of the organic solvent include alcohols (eg, ethanol, methanol, polyethylene glycol); aprotic solvents such as N,N-dimethylformamide and dimethyl sulfoxide; and combinations of two or more thereof.

[0111] Examples of the surfactant include anionic surfactants (e.g., sodium lauryl sulfate, sodium cholate, sodium deoxycholate), cationic surfactants (e.g., cetyltrimethylammonium bromide), nonionic surfactants (e.g., octylphenol ethoxylate, polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyoxyethylene stearyl ether, polyoxyethylene sorbitan monolaurate), and amphoteric surfactants (e.g., 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonic acid), but are not limited thereto.

[0112] Examples of the chelating agent include ethylenediaminetetraacetic acid (EDTA), glycol ether diaminetetraacetic acid (EGTA), nitrilotriacetic acid (NTA), phenanthroline, maleic acid, citric acid, tris(hydroxymethyl)methylglycine, trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA), tartaric acid, nicotinamide, hydroxyethyliminodiacetic acid (HIDA), phytic acid, etc., but are not limited to these.

[0113] Examples of proteins include, but are not limited to, bovine serum albumin (BSA). By adding proteins such as BSA, enzymes can be stabilized or adsorption of reaction components to a container can be suppressed.

[0114] 7.(ii) Ligation of the Additional Oligo to the Second Linker

[0115] The method for connecting the additional oligomer to the second linker is not particularly limited, and is preferably carried out by an enzyme reaction, more preferably using a polynucleotide ligase, and particularly preferably a DNA ligase. When using a polynucleotide ligase, the source of the enzyme is not particularly limited, and it is preferred to use a DNA ligase derived from T4 phage, a DNA ligase derived from T3 phage, a DNA ligase derived from T7 phage, a DNA ligase derived from Escherichia coli or a mutant thereof, or a DNA ligase such as Ampligase (registered trademark) thermostable DNA ligase sold by Lucigen.

[0116] In addition, when the additional oligomer is spaced by more than one base from the second linker, the gap can be filled by the enzyme reaction of DNA polymerase, etc. (gap repair). The gap repair can be carried out simultaneously with the connection using polynucleotide ligase, or can be carried out separately. As the enzyme used when performing gap repair and connection, there is no particular restriction, and preferably DNA polymerase and polynucleotide ligase are used. As DNA polymerase, there is no particular restriction, preferably DNA polymerase derived from T4 phage, DNA polymerase I derived from Escherichia coli, or Klenow fragment as a fragment of DNA polymerase I derived from Escherichia coli, more preferably DNA polymerase derived from T4 phage, etc., which hardly show DNA strand displacement activity. As polynucleotide ligase, the source of the enzyme is not particularly limited, and preferably a heat-resistant DNA ligase such as Ampligase (registered trademark) heat-resistant DNA ligase sold by Lucigen, a DNA ligase derived from T4 phage, and a DNA ligase derived from Escherichia coli.

[0117] When the enzymes as described above are used to carry out the connection of the additional oligomer and the second linker by enzyme reaction, the concentrations of these enzymes are not particularly limited as long as they show activity, and the concentration of the polynucleotide ligase is preferably 0.01U / μL or more, and the concentration of the DNA polymerase is preferably 0.005U / μL or more. In addition, the reaction solution used in the connection treatment by the enzyme reaction is not particularly limited as long as it is a reaction solution that can exert enzyme activity, and other additives may be included. For example, it is known that polynucleotide ligases such as DNA ligase derived from T4 phage need adenosine triphosphate (ATP) to exert activity, and polynucleotide ligases such as DNA ligase derived from Escherichia coli need nicotinamide adenine dinucleotide (NAD) to exert activity. In addition, deoxyribonucleotides are usually required for DNA polymerase to exert activity. In addition, for example, buffers, salts, organic solvents, polymers, surfactants, chelating agents, proteins, combinations of two or more of these, etc. can be used as additives.

[0118] Examples of the buffer include Tris, Bis-Tris, Tricine, Bis-Tricine, Hepes, Mops, Tes, Taps, Pipes, Caps, phosphoric acid, acetic acid, and combinations of two or more thereof. The buffer is usually dissolved in water (preferably nuclease-free water) and used in the form of an aqueous solution.

[0119] Examples of the salt include chlorides (e.g., lithium chloride, sodium chloride, potassium chloride, magnesium chloride, manganese chloride, and ammonium chloride), acetates (e.g., lithium acetate, sodium acetate, potassium acetate, magnesium acetate, manganese acetate, and ammonium acetate), sulfates (e.g., potassium sulfate, magnesium sulfate, manganese sulfate, and ammonium sulfate), and combinations of two or more thereof.

[0120] Examples of the organic solvent include alcohols (eg, ethanol, methanol, polyethylene glycol); aprotic solvents such as N,N-dimethylformamide and dimethyl sulfoxide; and combinations of two or more thereof.

[0121] Examples of the surfactant include anionic surfactants (e.g., sodium dodecyl sulfate, sodium cholate, sodium deoxycholate), cationic surfactants (e.g., cetyltrimethylammonium bromide), nonionic surfactants (e.g., octylphenol ethoxylate, polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyoxyethylene stearyl ether, polyoxyethylene sorbitan monolaurate), and amphoteric surfactants (e.g., 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonic acid), but are not limited thereto.

[0122] Examples of the chelating agent include ethylenediaminetetraacetic acid (EDTA), glycol ether diaminetetraacetic acid (EGTA), nitrilotriacetic acid (NTA), phenanthroline, maleic acid, citric acid, tris(hydroxymethyl)methylglycine, trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA), tartaric acid, nicotinamide, hydroxyethyliminodiacetic acid (HIDA), phytic acid, etc., but are not limited to these.

[0123] Examples of proteins include, but are not limited to, bovine serum albumin (BSA). By adding proteins such as BSA, enzymes can be stabilized or adsorption of reaction components to a container can be suppressed.

[0124] Alternatively, the reaction solution used in step (i) (transposase treatment) may be used as it is, or the above-mentioned enzyme may be added thereto to carry out step (ii) (ligation of the additional oligomer and the second linker).

[0125] 8. (iii) Ligation of the non-transferred linker to double-stranded DNA

[0126] The method for connecting the non-transferred strand (e.g., the second linker) to the double-stranded DNA is not particularly limited, and is preferably performed by an enzyme reaction. When the linker of the non-transferred strand is connected to the double-stranded DNA by an enzyme reaction, the 5' end of the non-transferred strand is preferably phosphorylated. In some embodiments, there is a situation where the transposase causes a gap of several bases between the non-transferred strand and the double-stranded DNA, so it is preferred to perform gap repair.

[0127] The gap repair between the linker of the non-transferred chain and the double-stranded DNA can be carried out simultaneously with the connection of the additional oligomer and the second linker of the above-mentioned (ii), or separately. In addition, the enzyme for connecting the additional oligomer and the second linker and the enzyme for connecting the linker of the non-transferred chain and the double-stranded DNA (iii) can be the same enzyme or different enzymes. There is no particular restriction on the enzyme used for gap repair and connection, and it is preferred to use DNA polymerase and polynucleotide ligase. As DNA polymerase, there is no particular restriction, and it is further preferred to use DNA polymerase derived from T4 phage, DNA polymerase I derived from Escherichia coli, or Klenow fragment as a fragment of DNA polymerase I derived from Escherichia coli, and it is more preferred to use enzymes that hardly show DNA chain displacement activity such as DNA polymerase derived from T4 phage. As a polynucleotide ligase, the source of the enzyme is not particularly limited, and it is preferred to use a heat-resistant DNA ligase such as Ampligase (registered trademark) heat-resistant DNA ligase sold by Lucigen, a DNA ligase derived from T4 phage, or a DNA ligase derived from Escherichia coli.

[0128] When the linker of the non-transferred chain is connected to the double-stranded DNA by enzyme reaction using the enzymes as described above, the concentration of these enzymes is not particularly limited as long as they show activity, and the concentration of the polynucleotide ligase is preferably 0.01U / μL or more, and the concentration of the DNA polymerase is preferably 0.005U / μL or more. In addition, the reaction solution used in the connection treatment using the enzyme reaction is not particularly limited as long as it is a reaction solution that can exert enzyme activity, and other additives may be included. As the other additives, for example, the same substances as the other additives described as other additives preferably used in the enzyme reaction in the connection of the additional oligomer and the second linker described above (ii) can be used.

[0129] 9. Reaction temperature and time of connection of (ii) and (iii)

[0130] The reaction conditions for connecting the additional oligomer to the second linker (ii) and connecting the linker of the non-transferred chain to the double-stranded DNA (iii) are not particularly limited, and the reaction conditions of the two steps may be the same or different. For example, when the two steps are performed under the same reaction conditions, the upper limit of the reaction temperature is not particularly limited. As an example, it is preferably the Tm value of the complementary sequence portion of the first linker and the second linker (particularly the complementary sequence portion of the first transposon end sequence and the second transposon end sequence) is below +15°C, and the Tm value of the complementary sequence portion of the first linker and the additional oligomer (particularly the complementary sequence portion of the region other than the first tag fragment sequence (preferably the region of any sequence of the first linker and / or a part of the first transposon end sequence)) and the complementary sequence portion of the additional oligomer (the region other than the second tag fragment sequence) is below +15°C, more preferably the Tm value of the complementary sequence portion of the first linker and the second linker is below +10°C, and the Tm value of the complementary sequence portion of the first linker and the additional oligomer is below +10°C. In one embodiment, it is preferably below 45°C, and more preferably below 37°C. In addition, the lower limit of the reaction temperature in this case is not particularly limited, but in order to maintain enzyme activity and reduce non-specific ligation, it is preferably 4° C. or higher, more preferably 10° C. or higher, and further preferably 15° C. or higher. In addition, when ligating by enzyme reaction, in order to avoid a decrease in enzyme activity due to low temperature or heat, it is preferred to maintain a temperature range in which the polynucleotide ligase activity is maintained at 10% or higher and the DNA polymerase activity is maintained at 10% or higher.

[0131] The reaction time is not particularly limited, and is, for example, preferably 5 minutes or longer, and more preferably 10 minutes or longer. The upper limit of the reaction time is not particularly limited, and can be, for example, 1 hour or shorter.

[0132] In the method for generating a double-stranded DNA library of the present invention, DNA purification may or may not be performed after any one or more of the above-mentioned steps (i), (ii) and (iii), or after all of these steps. In addition, when performing the PCR reaction described later, DNA purification may or may not be performed before the PCR. Furthermore, when performing NGS analysis using the double-stranded DNA library generated by the present invention, DNA purification may or may not be performed before the NGS analysis. DNA purification can be performed by any method known in the art, for example, a method using AMPure XP (Beckman Coulter), adsorption beads similar thereto, and a method using ethanol or polyethylene glycol to reduce solubility, without particular limitation.

[0133] 10. Polymerase chain reaction (PCR)

[0134] After the tag fragment sequence is added by the present invention (after the steps (i), (ii) and (iii) are completed), it can be used for various purposes. In the present invention, impurities such as linker dimers are not generated when the Y-shaped linker is added, so it can be directly used for various purposes without purification. For example, a primer pair designed in a manner that respectively binds to different tag fragment sequences added to the 5' end side and the 3' end side can be used to amplify the tagged fragmented double-stranded DNA by any nucleic acid amplification method such as PCR. In addition, a new tag fragment sequence can be added by a nucleic acid amplification method such as PCR. Examples of the tag fragment sequence added by a nucleic acid amplification method such as PCR include, for example, NGS equipment used in Illumina and the like (such as NextSeq TM 、MiSeq TM There are no particular limitations on the index sequence of a sequence used for sequencing a target DNA sequence (e.g., a sequence of ...

[0135] 11. Retention of chain information

[0136] The library prepared by the present invention may or may not retain the chain information. There is no particular limitation on the target double-stranded DNA when retaining the chain information. For example, when synthesizing cDNA from RNA and then synthesizing DNA complementary to the cDNA, a double-stranded DNA containing uracil in only one side of the chain is prepared by synthesizing in a reaction solution containing dUTP, and in subsequent steps, UNG (uracil DNA glycosylase) is used for treatment and / or PCR is performed using a DNA polymerase that cannot use uracil as a template (e.g., a DNA polymerase of the B family), thereby avoiding the amplification of DNA chains containing uracil. Thus, for example, in subsequent sequencing analysis, the chain information can be retained and each DNA chain can be analyzed.

[0137] 12. Bisulfite Sequence Analysis

[0138] According to the present invention, bisulfite sequence analysis, especially T-WGBS (Tagmentation-based whole-genome bisulfite sequence, whole genome bisulfite sequence based on tag fragmentation) analysis can also be easily implemented. For example, the cytosine bases in the first tag fragment sequence region of the first linker and the cytosine in the second tag fragment sequence region of the attached oligomer are methylated, and on this basis, a library is generated from double-stranded DNA, and treated with bisulfite (bisulfite) and the like, thereby detecting the methylation state of cytosine in the double-stranded DNA. As such a bisulfite sequence analysis, for example, it can be implemented with reference to the method described in Adey A. et al., Genome Res. 22, 1139-1143, 2012.

[0139] Therefore, in one embodiment, the present invention can be a method for generating a double-stranded DNA library for bisulfite analysis using the above-mentioned first linker in which the cytosine base in the above-mentioned first tag fragment sequence has been methylated and the above-mentioned additional oligomer in which the cytosine base in the above-mentioned second tag fragment sequence has been methylated. Utilizing this method, methylation analysis of double-stranded DNA in which at least one chain has been methylated can be performed.

[0140] 13. Double-stranded DNA

[0141] In the present invention, the double-stranded DNA (also referred to as target double-stranded DNA, etc.) that is the object is not particularly limited, and examples thereof include genomic DNA extracted from cells, double-stranded DNA amplified by methods such as PCR, double-stranded DNA synthesized from RNA, etc. In addition, the double-stranded DNA may be not only double-stranded DNA derived from one cell, tissue, organ, organism (e.g., animal, plant, fungus, bacteria, virus, etc.), but also double-stranded DNA derived from multiple cells, tissues, organs, organisms. The amount of double-stranded DNA used in the present invention is not particularly limited.

[0142] 14. Double-stranded DNA library generation kit

[0143] The present invention can also be in the form of a kit for generating a double-stranded DNA library having different tag fragment sequences at the 5' end side and the 3' end side. The kit at least comprises a transposome, and the transposome comprises: (a) a first linker, which comprises a first tag fragment sequence and a first transposon end sequence, (b) a second linker, which comprises a second transposon end sequence having a base sequence complementary to at least a portion of the above-mentioned first transposon end sequence, and (c) a transposase. In addition, the kit preferably also comprises enzymes such as polynucleotide ligase and DNA polymerase. These (a) to (c) components, enzymes, and other additives that may be optionally included may be in the form of a mixture in which each component is optionally mixed, or may be in the form of a kit having each component separately.

[0144] Example

[0145] The present invention will be described in more detail below based on examples, but the present invention is not limited to these examples.

[0146] (Preparation of transposomes)

[0147] First, before the examples, as preparation of transposase, a gene encoding a protein whose C-terminus was modified with a histidine tag using a super-active Tn5 (Tn5 transposase mutant (E54K / L372P mutant) described in Picelli et al., Genome Res. 24 (12): 2033-40, 2014) was inserted into an expression plasmid and transformed into Escherichia coli DH5α strain. The Escherichia coli strain was cultured at 30°C, suspended in 50mM HEPES-KOH (pH 8.0), 100mM NaCl, and disrupted by ultrasonic treatment. The crushed liquid was then subjected to affinity chromatography using TALON (trademark) affinity resin (ClonTech), and after binding, it was washed with 50mM HEPES-KOH (pH 8.0), 100mM NaCl, and 10mM imidazole, and eluted with 50mM HEPES-KOH (pH 8.0), 100mM NaCl, and 150mM imidazole to obtain purified ultra-high activity Tn5. The purified ultra-high activity Tn5 was dialyzed in 50mM HEPES-KOH (pH 7.5), 100mM NaCl, 1mM dithiothreitol (DTT), and 50% glycerol for buffer exchange, and the protein concentration was diluted to 100μg / mL with dialysis buffer to prepare a "purified Tn5 solution". In addition, in order to prepare the linker provided to the transposase, the three sets of linkers shown in Table 1 below were first prepared.

[0148]

Table 1

[0149] Table 1. Linker groups used in Example 1

[0150]

[0151] For these adapter sets, a solution was prepared in a solution of 50 mM HEPES-KOH (pH 7.5) and 100 mM NaCl so that the concentration of the first adapter and the second adapter was 5 μM, and the solution was heated to 100° C. Then, the adapter was annealed by cooling to 25° C. at a rate of Δ-1° C. / min. After annealing, an equal amount of 100% glycerol was mixed to prepare each “adapter solution (1, 2, 3)” adjusted to 50% glycerol.

[0152] Furthermore, 6 μL of any one of the linker solutions (1, 2, 3) was added to 24 μL of the purified Tn5 solution, and the mixture was allowed to stand at 25°C for 60 minutes to provide each linker, and then diluted 100-fold with dialysis buffer to prepare "Tn5 (linker 1)", "Tn5 (linker 2)", and "Tn5 (linker 3)".

[0153] In addition, as negative controls, the same operation was performed on three linker sets shown in the following Table 2, in which the 5' side of the second linker (non-transferred chain) was not phosphorylated and could not bind to the target double-stranded DNA in an additional reaction using DNA ligase, etc., to prepare "Tn5 (Linker 1NC)", "Tn5 (Linker 2NC)", and "Tn5 (Linker 3NC)".

[0154] It should be noted that the prepared "Tn5 (linker 1)", "Tn5 (linker 2)", "Tn5 (linker 3)", "Tn5 (linker 1NC)", "Tn5 (linker 2NC)", and "Tn5 (linker 3NC)" were used to evaluate the degradation of human genomic DNA for activity measurement, and it was confirmed that all showed activity. In addition, the presence or absence of phosphorylation on the 5' side of the linker did not affect the transfer activity of the transposome.

[0155]

Table 2

[0156] Table 2. Negative controls used in Example 1

[0157]

[0158] In Table 2, the underline (solid line) represents the first tag fragment sequence, and the underline (dashed line) represents the first transposon end sequence.

[0159] (Preparation of additional oligomers)

[0160] Furthermore, the additional oligomers shown in Table 3 to be used together with these linker sets were prepared at 10 μM.

[0161]

Table 3

[0162] Table 3

[0163]

[0164] In Table 3, the underline indicates the second tag fragment sequence.

[0165] (Preparation of reaction buffer)

[0166] In addition, as reaction buffers, Tn5 reaction buffer (20 mM Tris-HCl (pH 7.5), 15% dimethylformamide, 10 mM MgCl2) and additional reaction buffer (300 mM Tris-HCl (pH 8.0), 40 mM MgCl2, 100 mM (NH4)2SO4, 12 mM EDTA (pH 8.0), 1 mM NAD, 0.05% BSA) were prepared.

[0167] Example 1: Preparation of NGS library using the present invention

[0168] In this example, the following experiments were conducted to examine whether the present invention can efficiently fragment target double-stranded DNA and efficiently prepare NGS libraries by adding tags with different sequences at the 5' and 3' ends.

[0169] First, a Tn5 reaction solution was prepared according to the composition of Table 4 using Tn5 (linker) obtained by the above-mentioned preparation method and genomic DNA (1 ng) purified from HeLa S3 cells as the target double-stranded DNA.

[0170]

Table 4

[0171] Table 4. Tn5 reaction solution

[0172]

[0173] The prepared reaction solution was reacted at 55°C for 5 minutes (linkers 1, 2, 1NC and 2NC) or at 50°C for 20 minutes (linkers 3 and 3NC) to perform fragmentation and addition of the first tag fragment sequence. After adding 2.5 μL of 0.15% sodium dodecyl sulfate solution to stop the reaction, the total amount of the additional reaction solution prepared according to the composition of Table 5 was added.

[0174]

Table 5

[0175] Table 5. Additional reaction solution 1

[0176] 10 μM additional oligo 1, 2 or 3 0.5μL Additional reaction buffer 1μL 10mM dNTPs (dATP, dTTP, dGTP, dCTP) 0.5μL 10U / mL E. coli DNA ligase (NEB) 0.05μL 3U / mL T4 DNA polymerase 0.05μL Sterilized water 1.9uL total 4μL

[0177] After adding the additional reaction solution, the additional reaction was carried out at 37°C for 15 minutes (linkers 1, 2, 1NC and 2NC) or at 20°C for 20 minutes (linkers 3 and 3NC) to add the second tag fragment sequence. The double-stranded DNA library thus obtained was used directly without nucleic acid purification, and the PCR reaction was carried out as follows.

[0178] A PCR reaction solution was prepared according to the composition of Table 6, and PCR was performed with the reaction cycle of Table 7 to add the index sequence and P5 and P7 sequences for NGS of Illumina.

[0179]

Table 6

[0180] Table 6. PCR reaction solution

[0181]

[0182]

Table 7

[0183] Table 7. Reaction cycle

[0184]

[0185] *4℃ condition is set to within 1 hour.

[0186] For the PCR product after the reaction, 24 μL of AMPure XP beads (Beckman Coulter) were used to purify the nucleic acid according to the manual, and eluted into 30 μL of TE buffer (Nacalai Tesque, Inc.) (purified PCR nucleic acid solution). Then, 3 μL of the purified PCR nucleic acid solution was electrophoresed using the SHIMADZU DNA / RNA analysis microchip electrophoresis device MultiNA according to the manual to confirm the pattern of the library product ( Figure 5 ). In addition, the library was quantified using the GenNext (registered trademark) NGS Library Quantification Kit (manufactured by Toyobo) according to the manual, and the library yield of Tn5 (linker 1) was calculated to be 120 nM, and the library yield of Tn5 (linker 1 NC) was 0.4 nM. The same results were obtained for Tn5 (linker 2) and Tn5 (linker 2 NC), Tn5 (linker 3) and Tn5 (linker 3 NC).

[0187] From these results, it can be seen that the present invention efficiently performs fragmentation and tag fragmentation, and can prepare a library for NGS of Illumina. In addition, the negative control has almost no yield, which shows that the additional oligomer is connected to the second linker as the non-transferred strand, and the second linker is connected to the target double-stranded DNA, thereby reacting.

[0188] Example 2: Preparation of NGS library retaining strand information using the present invention

[0189] In this example, the following experiments were conducted to investigate whether the present invention can efficiently fragment, tag, fragment, and prepare a library for NGS using double-stranded cDNA derived from RNA as a target, and further investigate whether the strand information can be retained.

[0190] First, cDNA was synthesized from 1 ng of RNA purified from HeLa S3 cells using RNeasy Plus Mini Kit (QIAGEN). To 9 μL of the cDNA solution, the second strand synthesis solution shown in Table 8 was added and the reaction was carried out according to the cycle shown in Table 9 to obtain double-stranded DNA from RNA.

[0191]

Table 8

[0192] Table 8. Second chain synthesis solution

[0193] DNA polymerase I large (Klenow) fragment (NEB) 0.25μL 100 mM Tris-HCl, pH 8.0 0.5μL 500mM NaCl 0.5μL <![CDATA[100mM MgCl2]]> 0.5μL 100mM DTT 0.05μL 2mM dNTPs (Toyobo Co., Ltd.) 0.5μL 2mM dUTP (Toyobo Co., Ltd.) 2μL or 0μL 10mM random primer 6mer 0.5μL Sterilized water 1.2μI or 3.2μL total 6μL

[0194]

Table 9

[0195] Table 9. Reaction cycle

[0196] temperature time 16℃ 60 minutes 70℃ 10 minutes 4℃ Keep*

[0197] *4C condition is set to within 1 hour.

[0198] For the double-stranded DNA from RNA after the reaction, 27 μL of AMPure XP beads (Beckman Coulter) were used to purify nucleic acids according to the manual, and the DNA was eluted into a mixture of 2.5 μL of Tn5 reaction buffer and 1.25 μL of sterile water (purified double-stranded DNA (derived from RNA)). Then, in the same manner as in Example 1, the obtained purified double-stranded DNA (derived from RNA) was used as the target double-stranded DNA, and a Tn5 reaction solution was prepared according to the composition of Table 10.

[0199]

Table 10

[0200] Table 10. Tn5 reaction solution

[0201] (from RNA) Purification of double-stranded DNA 3.75μL Tn5 (adapter 1, 2 or 3) 1.25μL total 5μL

[0202] The prepared reaction solution was reacted at 55°C for 5 minutes (linkers 1 and 2) or at 50°C for 20 minutes (linker 3) to perform fragmentation and addition of the first tag fragment sequence. After adding 2.5 μL of 0.15% sodium dodecyl sulfate solution to stop the reaction, the total amount of the additional reaction solution prepared according to the composition of Table 5 was added.

[0203] After adding the additional reaction solution, the additional reaction was carried out at 37°C for 15 minutes (linkers 1 and 2) or at 20°C for 20 minutes (linker 3) to add the second tag fragment sequence. The double-stranded DNA library thus obtained was used directly without nucleic acid purification, and the PCR reaction was carried out as follows.

[0204] The PCR reaction solution was prepared according to the composition of Table 6, and PCR was performed with the reaction cycle of Table 7 to add the index sequence and P5 and P7 sequences for NGS of Illumina. It should be noted that in the PCR reaction solution, a DNA polymerase derived from KOD (Thermococcus kodakarensis) belonging to the B family that cannot amplify base sequences containing uracil was used.

[0205] For the PCR product after the reaction, 24 μL of AMPure XP beads (Beckman Coulter) were used to purify the nucleic acid according to the manual, and eluted into 30 μL of TE buffer (Nacalai Tesque, Inc.) (purified PCR nucleic acid solution). Then, 3 μL of the purified PCR nucleic acid solution was electrophoresed using the SHIMADZU DNA / RNA analysis microchip electrophoresis device MultiNA according to the manual to confirm the pattern of the library product ( Figure 6 ). In addition, the library was quantified using GenNext (registered trademark) NGS Library Quantification Kit (Toyobo Co., Ltd.) according to the manual, and the results of Tn5 (linker 1) were calculated as follows: 83 nM without the addition of dUTP and 37 nM with the addition of dUTP. The same results were obtained for Tn5 (linker 2) and Tn5 (linker 3).

[0206] From these results, it can be seen that the present invention can efficiently fragment and tag cDNA derived from RNA, and can prepare a library for NGS of Illumina. Furthermore, the yield was about half of that obtained under the condition containing dUTP, and it is believed that amplification from the second strand cannot be performed by using a polymerase that cannot amplify using uracil as a template. This result shows that the double-stranded DNA library obtained by the method of this example is composed of substances amplified from the first strand, and the strand information is retained.

[0207] Example 3: NGS analysis of the library prepared using the present invention

[0208] The genomic DNA or RNA-derived double-stranded DNA (without or with dUTP) in the double-stranded DNA library obtained in Example 1 and Example 2 was treated with Tn5 (linker 1), Tn5 (linker 2), and Tn5 (linker 3), and the prepared library was used for NGS analysis using Miseq Reagent Kit v3 and Miseq. It should be noted that when analyzing linker 1 and linker 2, the following custom primers were added to the specified sequencing primer solution as sequencing primers. In the analysis of linker 3, the Read1 primer, Read2 primer, and Index1Read primer attached to the Miseq Reagent Kit v3 were used.

[0209] Read1 Primer for Adapter 1:

[0210] 5'-GCGTCCTCGTGTGCTACTTGAAGATGTGTATAAGAGACAG-3' (SEQ ID NO: 12)

[0211] Read2 Primer for Adapter 1:

[0212] 5'-CTCGGCTCGTGTGCTACTTGAAGATGTGTATAAGAGACAG-3' (SEQ ID NO: 13)

[0213] Index1 Read Primer for Adapter 1:

[0214] 5'-TCAAGTAGCACACGAGCCGAGCCCACGAGAC-3' (SEQ ID NO: 14)

[0215] Read1 Primer for Adapter 2:

[0216] 5'-GGCAGCGTCAGCTAGCTAGCAGATGTGTATAAGAGACAG-3' (SEQ ID NO: 15)

[0217] Read2 Primer for Adapter 2:

[0218] 5'-GTGGGCTCGGAGCTAGCTAGCAGATGTGTATAAGAGACAG-3' (SEQ ID NO: 16)

[0219] Index1 Read Primer for Adapter 2:

[0220] 5'-ACATCTGCTAGCTAGCTCCGAGCCCACGAGAC-3' (SEQ ID NO: 17)

[0221] The NGS data obtained by using the CLC Genomics Workstation were analyzed for mapping rate and strand rate to the human genome. The results are shown in Table 11.

[0222]

Table 11

[0223] Table 11. NGS analysis results

[0224]

[0225] This result shows that the method for generating a double-stranded DNA library of the present invention can efficiently generate a double-stranded DNA library that can be used for sequence analysis such as NGS through simple steps.

[0226] Industrial Applicability

[0227] According to the present invention, a library for gene analysis such as next generation sequencer (NGS) analysis can be prepared simply and quickly.

Claims

1. A method for generating a double-stranded DNA library having different tag fragment sequences at the 5' end and the 3' end, comprising the following steps (i) to (iii): (i) fragmenting the double-stranded DNA using a transposome, and connecting any one of the following first linker and the following second linker to the 5' end or the 3' end of the double-stranded DNA as a transfer strand, wherein the transposome comprises: (a) a first adapter, which comprises a first tag fragment sequence and a first transposon end sequence, (b) a second adaptor comprising a second transposon end sequence having a base sequence complementary to at least a portion of the first transposon end sequence, and (c) transposase; (ii) a step of connecting an additional oligomer containing a second tag fragment sequence to the second linker; and (iii) a step of ligating the non-transferred strand linker of the first linker and the second linker that is not linked to the double-stranded DNA to the end of the 5' end and the 3' end of the double-stranded DNA that is not linked to the transferred strand linker in the step (i), The step (ii) is carried out before or after the step (iii), or simultaneously with the step (iii).

2. The method according to claim 1, wherein: The first adaptor contains a first tag fragment sequence at the 5′ end side of the first transposon end sequence, and the first adaptor becomes a transferred strand ligated to the 5′ end of the double-stranded DNA by a transposase.

3. The method according to claim 1, wherein: The additional oligomer comprises a base sequence complementary to a portion of the base sequence of the first linker.

4. The method according to claim 1, wherein: The transposase is a highly active Tn5 transposase, and the first transposon end sequence and the second transposon end sequence are Tn5-type transposon end sequences.

5. The method according to claim 1, wherein: In the step (ii), the additional oligomer is ligated to the second linker using DNA ligase.

6. The method according to claim 1, wherein: In the step (iii), the linker that is not ligated to the non-transferred strand of the double-stranded DNA is ligated to the double-stranded DNA using a DNA polymerase and a DNA ligase.

7. The method according to claim 1, wherein: In the step (iii), the linker not ligated to the non-transferred strand of the double-stranded DNA is a second linker whose 5' terminal side is phosphorylated, and the second linker is ligated to the 3' terminal of the double-stranded DNA.

8. The method according to claim 1, wherein: In the step (i), a first adapter is ligated to the 5' end of the double-stranded DNA as a transferred strand, and in the step (ii), an additional oligomer whose 5' end side is phosphorylated is ligated to the 3' end of the second adapter.

9. The method according to claim 1, wherein: In the step (i), a first linker is linked to the 5' end of the double-stranded DNA as a transferred strand, and in the step (ii), an additional oligomer having a modified OH group at the 3' end is linked to the 3' end of the second linker.

10. The method according to claim 9, wherein: The modification of the OH group is modification using a phosphate group or reverse dT.

11. The method according to claim 1, wherein: Generate a double-stranded DNA library that preserves strand information.

12. The method according to claim 1, wherein: At least one strand of the double-stranded DNA is modified.

13. The method according to claim 12, wherein: The modification is a methylation modification.

14. The method according to claim 12, wherein: The first adaptor in which the cytosine base in the first tag fragment sequence is methylated and the additional oligomer in which the cytosine base in the second tag fragment sequence is methylated are used to generate a double-stranded DNA library for bisulfite analysis.

Images